Dichlorobenzyl Alcohol
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Dichlorobenzyl Alcohol: From Sore Throat Lozenge Use to Bronchitis
One-Sentence Summary
Dichlorobenzyl alcohol is a mild topical antiseptic used in throat lozenges marketed in Canada. The TxGNN model predicts it may be effective for bronchitis, but there are 0 clinical trials and only 1 publication (which concerns a different drug), so this prediction rests on computation alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Canadian licence records (products are marketed as throat lozenges) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 0.9921 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, dichlorobenzyl alcohol is a topical antiseptic used in throat lozenges, with local antibacterial and antiviral activity and a weak local anaesthetic effect.
These properties could plausibly relieve upper respiratory symptoms such as sore throat. However, bronchitis involves inflammation of the lower airways, which a lozenge-delivered local antiseptic is not expected to reach or act upon. No mechanistic link to bronchitis has been established.
The high TxGNN score is a computational prediction only. The data compiled for this report contain no clinical or mechanistic evidence to support it.
A second predicted indication, migraine disorder (score 0.9902), has no clinical trials, no literature, and no plausible mechanistic link. It is also rated L5 / Hold.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1036939 | 1976 | Case report / pharmacology note | Arzneimittel-Forschung | Describes raised creatine kinase activity in 25 chronic bronchitis patients treated with clenbuterol, a different compound (a beta2-agonist bronchodilator). It does not study dichlorobenzyl alcohol and does not support this prediction. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02375567 | Antibacterial Throat Lozenges | Not stated | Not stated |
| 02382938 | Cepacol Sensations | Not stated | Not stated |
| 02404982 | Cepacol Children’s Fruity Strawberry | Not stated | Not stated |
| 02388642 | Cepacol Sensations Sore Throat & Cough | Not stated | Not stated |
| 02382881 | Cepacol Sensations Sore Throat & Blocked Nose | Not stated | Not stated |
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the data compiled for this report, and no disease contraindications were identified from the knowledge graph.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has only a model score behind it. There are no clinical trials, the single retrieved publication concerns a different drug, and the drug’s local lozenge action does not plausibly address lower-airway inflammation. Package insert warnings and contraindications are also missing, so safety screening cannot proceed.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data for dichlorobenzyl alcohol
- Approved indication text and dosage forms for the five licensed products
- Preclinical or clinical evidence that the drug has any effect on bronchitis
- Assessment of whether a lozenge route can reach the lower airways
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.